7/12/2011

A slew of best-selling drugs will soon lose patent protection, but innovative drugs in the pipeline are likely to receive FDA approval and could soften pharma's fall off the so-called patent cliff. Bristol-Myers Squibb moved to encourage collaboration with outside researchers, resulting in the development of an innovative drug that uses the immune system to target melanoma, said Elliott Sigal, Bristol's head of research and development. "We're seeing a lot of innovation, much more than in recent memory," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Related Summaries